COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options
Authors:
Open Access
- 25 January 2021
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 10 (1) , 93-113
Abstract
The 2019 novel coronavirus (COVID-19) has quickly become one of the most dire international pandemic crises since the 1918 Spanish flu. Evidence for COVID-19 pharmacological therapies has shown rapid growth and a diverse array of results, but an assessment of the value of each piece of evidence must be reinforced. This article aims to review utilized therapies, the evidence level supporting these therapies, as well as drugs under investigation for the treatment of COVID-19. Primary scrutinized therapies include antiviral regimens, such as remdesivir, hydroxychloroquine/chloroquine, lopinavir/ritonavir, immunomodulating drugs, such as corticosteroids and interleukin (IL) inhibitors, and other therapies including convalescent plasma. Only one therapy, dexamethasone, has shown a mortality benefit in randomized controlled trials and summarized evidence for other therapies show limited positive results. Reviewing these therapies in a historical way shows how limited evidence can drive therapy decisions. A broad summary of available evidence can assist clinicians in a return to hierarchical assessments of evidence which can lead to safer patient outcomes, improved distribution of resources, and better targets for appropriate therapy decisions.Keywords
This publication has 96 references indexed in Scilit:
- Assays for the Identification of Novel Antivirals against Bluetongue VirusJournal of Visualized Experiments, 2013
- Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune responseMicrobes and Infection, 2013
- Azithromycin induces anti-viral responses in bronchial epithelial cellsEuropean Respiratory Journal, 2010
- A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replicationProceedings of the National Academy of Sciences, 2008
- The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort studyJournal of Infection, 2005
- Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral DrugsEmerging Infectious Diseases, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Knowledge and level of consciousness: application to nursing practiceJournal of Advanced Nursing, 1994
- Animal toxicity and pharmacokinetics of hydroxychloroquine sulfateThe American Journal of Medicine, 1983
- Alfred W. Crosbyjr., Epidemic and peace, 1918, London, Greenwood Press, 1976, 8vo, pp. vi, 337, $17.50.Medical History, 1978